Geriatric Oncology Assessment and Coping Skills Training for Older Women on Aromatase Inhibitor Therapy

Starting soon · Not applicable

Conditions studied: Breast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia

In brief

Older women (≥65 years) with HR+ non-metastatic breast cancer experience high symptom burden and reduced quality of life during aromatase inhibitor (AI) therapy. This hierarchical 2×2 factorial randomized controlled trial will test two interventions: (1) a clinic-level geriatric oncology assessment and support program (GOAL-AI) and (2) a patient-level CBT-based coping skills training (CST-AI). The study aims to improve pain, symptom burden, and health-related quality of life compared to enhanced usual care.

Key facts

Study ID

NCT07232056

Run by

Duke University

People needed

452

Starts

2026-10-15

Expected to finish

2030-11-30

Last updated by the study team

2026-07-29

Who can join

Age: 65 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, age ≥65 years
• HR+ non-metastatic breast cancer
• Within 12 months of starting AI therapy
• English-speaking
• Able to provide consent

You may not qualify if…

• Age <65 years
• Metastatic cancer
• Cognitive impairment preventing consent
• Receiving care at multiple participating sites

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.